VALORIZATION
Translating research in AFFORDABLE PRODUCTS
“Health systems in many disease endemic countries are noticeably weak. Patients either cannot afford or do not have access to adequate drugs, while human and other resources are overburdened by the volume of needs (global report for research on infectious disease of poverty)”. The need to develop systems that make treatments available for neglected diseases is substantial.
Despite major progress during the past ten years in initiating and expanding programs targeting the neglected tropical diseases, many drugs or vaccines face major challenges to scaling up.
This inability to bring affordable and effective products on the market impacts hundreds of millions of people, especially in developing countries, impeding the access to simple interventions that promote health and prevent morbidity and unnecessary mortality. Artemis investigates barriers to innovations and develops strategies to overcome the barriers and stimulate marketing of products.
VALORIZATION PROJECTS:
- Rabies
- Influenza
THE IMPORTANCE OF MAKING NEW INTERVENTION STRATEGIES AVAILABLE TO DEVELOPING COUNTRIES
RESEARCH PROJECTS
The following viruses are being studied currently, embedded in several projects.
RABIES
Rabies virus (RABV), a member of the Lyssavirus genus is transmitted by the bite or scratches of infected animals (primarily dogs but also by cats, wildlife and bats), causes rabies encephalitis and accounts for more than 55,000 reported fatal human cases each year… > LEARN MORE
INFLUENZA
A universal influenza vaccine is one of the largest unmet medical needs. Yearly 250,000 to 500,000 people die from seasonal influenza, and on average 3 to 5 million hospitalizations occur each year… > LEARN MORE
RESEARCH FOCUS OVERVIEW WITHIN ARTEMIS:
ZOONOTIC VIRUSES ARBOVIRUSES VALORIZATION ANIMAL
VIEW RESEARCH FOCUS AREAS
Quick view ALL “ONGOING” projects:
Compare | Chikungunya | Yellow fever | Zika | Elepant Herpes virus | Rabies | Influenza | Dengue | EcoAlert | Zapi | Flucop | Flunivac | TBEV-COMEIN